These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1337249)

  • 1. Different pharmacokinetics, antithrombotic activity and bleeding effects of heparin and two new fragments administered in rat by subcutaneous route.
    Bergonzini GL; Bianchini P; Mascellani G; Osima B; Parma B; Volpi N
    Arzneimittelforschung; 1992 Nov; 42(11):1322-8. PubMed ID: 1337249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low molecular weight heparins: antithrombotic and haemorrhagic effects and standardization.
    Barrowcliffe TW; Thomas DP
    Acta Chir Scand Suppl; 1988; 543():57-64. PubMed ID: 2847459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins.
    Fareed J; Walenga JM; Hoppensteadt D; Huan X; Racanelli A
    Haemostasis; 1988; 18 Suppl 3():3-15. PubMed ID: 2840372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between plasma antifactor Xa activity and the antithrombotic activity of heparins of different molecular mass.
    Bianchini P; Bergonzini GL; Parma B; Osima B
    Haemostasis; 1995; 25(6):288-98. PubMed ID: 8586320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New data on the pharmacology of heparin and low molecular weight heparins.
    Samama MM; Bara L; Gouin-Thibault I
    Drugs; 1996; 52 Suppl 7():8-14; discussion 14-5. PubMed ID: 9042555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.
    Verstraete M
    Drugs; 1990 Oct; 40(4):498-530. PubMed ID: 1964634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative human pharmacology of low molecular weight heparins.
    Harenberg J; Stehle G; Augustin J; Zimmermann R
    Semin Thromb Hemost; 1989 Oct; 15(4):414-23. PubMed ID: 2554502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue distribution of the low molecular weight heparin, tinzaparin, following administration to rats by the oral route.
    Hiebert LM; Wice SM; Ping T
    Biomed Pharmacother; 2004; 58(6-7):372-80. PubMed ID: 15271419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic effect of OP/LMWH by subcutaneous route in rats.
    Fantuz M; Milani R; Andriuoli G; Mastacchi R; Barbanti M
    Arch Int Pharmacodyn Ther; 1986 Aug; 282(2):328-34. PubMed ID: 3767531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An approach to assigning in vitro potency to unfractionated and low molecular weight heparins based on the inhibition of prothrombin activation and catalysis of thrombin inhibition.
    Ofosu FA; Smith LM; Anvari N; Blajchman MA
    Thromb Haemost; 1988 Oct; 60(2):193-8. PubMed ID: 2851191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental studies on the antithrombotic and haemorrhagic effects of heparin and a low molecular weight heparin derivative.
    Kaiser B; Hauptmann J; Markwardt F
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):119-25. PubMed ID: 2459005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Supersulfated" heparin fragments, a new type of low-molecular weight heparin. Physico-chemical and pharmacological properties.
    Naggi A; Torri G; Casu B; Pangrazzi J; Abbadini M; Zametta M; Donati MB; Lansen J; Maffrand JP
    Biochem Pharmacol; 1987 Jun; 36(12):1895-900. PubMed ID: 3593400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Hirsh J; Raschke R
    Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synopsis of the anticoagulant and antithrombotic profile of the low molecular weight heparinoid Org 10172 in experimental models.
    Meuleman DG
    Semin Thromb Hemost; 1989 Oct; 15(4):370-2. PubMed ID: 2479103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-molecular-weight heparins for the treatment of deep-vein thrombosis.
    Cziraky MJ; Spinler SA
    Clin Pharm; 1993 Dec; 12(12):892-9. PubMed ID: 8137606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The new heparins].
    Samama M; Babinet-Berthier A
    J Mal Vasc; 1992; 17(2):91-106. PubMed ID: 1319447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human urinary soluble thrombomodulin (MR-33) improves disseminated intravascular coagulation without affecting bleeding time in rats: comparison with low molecular weight heparin.
    Takahashi Y; Hosaka Y; Imada K; Adachi T; Niina H; Watanabe M; Mochizuki H
    Thromb Haemost; 1997 Apr; 77(4):789-95. PubMed ID: 9134660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
    Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
    Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of antifactor Xa activity of heparins and antithrombotic efficacy.
    Harenberg J
    Haemostasis; 1988; 18 Suppl 3():16-9. PubMed ID: 3294127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why low molecular weight heparin?
    Mammen EF
    Semin Thromb Hemost; 1990 Oct; 16 Suppl():1-4. PubMed ID: 1962897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.